1. Home
  2. DTST vs SCYX Comparison

DTST vs SCYX Comparison

Compare DTST & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DTST
  • SCYX
  • Stock Information
  • Founded
  • DTST 2001
  • SCYX 1999
  • Country
  • DTST United States
  • SCYX United States
  • Employees
  • DTST N/A
  • SCYX N/A
  • Industry
  • DTST EDP Services
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DTST Technology
  • SCYX Health Care
  • Exchange
  • DTST Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • DTST 32.6M
  • SCYX 32.3M
  • IPO Year
  • DTST N/A
  • SCYX 2014
  • Fundamental
  • Price
  • DTST $4.16
  • SCYX $0.66
  • Analyst Decision
  • DTST Hold
  • SCYX Strong Buy
  • Analyst Count
  • DTST 1
  • SCYX 1
  • Target Price
  • DTST N/A
  • SCYX $3.00
  • AVG Volume (30 Days)
  • DTST 59.1K
  • SCYX 573.5K
  • Earning Date
  • DTST 11-14-2025
  • SCYX 11-13-2025
  • Dividend Yield
  • DTST N/A
  • SCYX N/A
  • EPS Growth
  • DTST N/A
  • SCYX N/A
  • EPS
  • DTST N/A
  • SCYX N/A
  • Revenue
  • DTST $25,455,742.00
  • SCYX $3,257,000.00
  • Revenue This Year
  • DTST N/A
  • SCYX $20.23
  • Revenue Next Year
  • DTST N/A
  • SCYX $933.90
  • P/E Ratio
  • DTST N/A
  • SCYX N/A
  • Revenue Growth
  • DTST 0.53
  • SCYX N/A
  • 52 Week Low
  • DTST $2.93
  • SCYX $0.65
  • 52 Week High
  • DTST $5.44
  • SCYX $1.49
  • Technical
  • Relative Strength Index (RSI)
  • DTST 44.42
  • SCYX 28.92
  • Support Level
  • DTST $4.10
  • SCYX $0.68
  • Resistance Level
  • DTST $4.38
  • SCYX $0.82
  • Average True Range (ATR)
  • DTST 0.16
  • SCYX 0.05
  • MACD
  • DTST 0.00
  • SCYX -0.01
  • Stochastic Oscillator
  • DTST 31.00
  • SCYX 4.07

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: